A nationally and internationally recognised expert in interstitial lung disease and pulmonary fibrosis, Dr Kulkarni’s research is centred on identifying imaging and clinical biomarkers that enhance prediction of disease progression and therapeutic response in ILD. She is actively involved as a principal and co-investigator in multiple clinical trials evaluating novel therapies, underscoring her commitment to translating research advances into meaningful clinical benefit.
Dr Kulkarni plays a highly active leadership role within major professional societies. She is Chair of the ILD Section at the American College of Chest Physicians (CHEST) and serves on several committees within the Pulmonary Fibrosis Foundation (PFF). She is also a member of the American Thoracic Society, contributing across organisations to education, collaboration and innovation in ILD care. Her work reflects a strong dedication to advancing standards of care while supporting professional development within the respiratory community.
In joining the Editorial Board, Dr Kulkarni is particularly interested in creating engaging educational content that translates emerging evidence into practical insights for clinicians. She is motivated by the opportunity to help shape the journal’s scientific direction, ensuring the publication of high-quality, clinically relevant research that improves diagnosis, treatment and quality of life for patients with ILD.
We are thrilled to welcome Dr Kulkarni to the touchREVIEWS in Respiratory & Pulmonary Diseases Editorial Board and look forward to her expertise, leadership and vision contributing to the continued growth and impact of the journal.
Editorial Board
Introducing the Editorial Board of touchREVIEWS in Respiratory & Pulmonary Diseases, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of respiratory and pulmonary healthcare worldwide.
👉 Read our previous interview with Dr Kulkarni from CHEST 2025: Clinical trials in fibrotic ILDs.
A quick 5-minute read exploring emerging therapeutic targets, the role of biomarkers, recruitment challenges, and the methodological advances shaping the future of fibrotic ILD research and patient care.
Cite: Dr Tejaswini Kulkarni joins our Editorial Board, bringing expertise in interstitial lung disease. touchRESPIRATORY. 19 December 2025.
touchREVIEWS in Respiratory & Pulmonary Diseases call for submissions!
👉 What We Offer:
- Peer-reviewed, free-to-access publications;
- Option for enhanced digital features and plain language summaries;
- Multiple article types: original research, reviews, editorials, commentaries and practice pearls; and
- We are supported by an esteemed editorial board.
For more details and to submit your research, visit our journal page.
Register now to receive the touchRESPIRATORY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
